Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program
2 How To Choose Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma
3 Adil Daud, MD, on the Importance of Testing Patients with Melanoma for BRAF Mutations
4 NICE backs Braftovi for BRAF-positive colorectal cancer
5 Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments
6 Selecting I/O or Targeted Therapy as Adjuvant Treatment of BRAF-Mutant Melanoma
7 BRAF and MEK Inhibitors Led to Acneiform Eruption, Acne-Inversa-Like Lesions in Patient With Advanced Melanoma
8 Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH trial subprotocol H
9 BRAF Kinase Inhibitors Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Array BioPharma Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, etc
10 Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
11 Targeted Drug BRAF Inhibitors for NSCLC Market with Report In Depth Industry Ana
12 Most Cost-effective to Use Immunotherapy First in Melanoma
13 Personalized Treatments, Overcoming Resistance Is Needed in Melanoma
14 NICE says yes to Braftovi combination for colorectal cancer
15 Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
16 Targeted Drug BRAF Inhibitors for NSCLC Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares And Forecast 2020-2027 | BeiGene, Novartis
17 Personalized Treatment Is Paramount in Colorectal Cancer
18 Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma
19 Anti-PD-1 in Melanoma Effective Regardless of BRAF Status
20 BRAF-Mutant Melanoma Field Continues to Move Forward
21 Sun’s Deborah James reveals cancer operation to remove 17th tumour ‘went well’ and she is recovering at home
22 Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors
23 'Viable' Responses With BRAF Inhibitor in Lung Cancer
24 Next generation BRAF inhibitor cancer drug shows promise in early patient trial
25 New BRAF Inhibitor Cancer Drug Shows Efficacy
26 Dabrafenib-trametinib combination active in BRAF -mutated biliary tract cancer
27 Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations: First prospective trial for rare patient population supports dabrafenib plus trametinib as new treatment option
28 Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer
29 FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation
30 Continuous dosing of BRAF and MEK inhibitors improves PFS in melanoma subset
31 Novellus, Plexxikon Enter Worldwide License Agreement for BRAF Inhibitor PLX8394
32 A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
33 Adjuvant dabrafenib-trametinib provides 'real chance to cure' BRAF -mutant melanoma
34 Adjuvant Dabrafenib + Trametinib in Resected Stage III Melanoma w/BRAF Mutations: 5-Year Follow-up
35 Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC
36 Insights into the Worldwide BRAF Mutated Non-Small Cell Lung Cancer (2018 to 2030)
37 Study offers new clues for treating brain cancer in children
38 RAF Inhibitor Plus Cobicistat Is Promising in BRAF+ Refractory Solid Tumors
39 Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
40 Moffitt Researchers Identify Driver of Further Metastasis in BRAF Inhibitor Resistant Melanoma
41 First Targeted Regimen Arrives for BRAF V600E-Mutant mCRC
42 Sequencing Debate for Frontline BRAF-Mutant Melanoma in Full Force
43 First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC
44 Tailoring the Understanding & Re-Education of Precision... : Oncology Times
45 Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma
46 A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
47 Braftovi Approved to Treat BRAF-Mutated CRC in Combination With Erbitux
48 Patients With BRAF-Mutated Bile Duct Cancer See Benefit from Targeted Treatment Combination
49 Triple Combination Prolongs Survival in Advanced BRAF V600... : Oncology Times
50 Spartalizumab-based combination fails in BRAF -mutated advanced melanoma
51 Novel Triplet Emerges as a Promising Option in BRAF-Mutant Melanoma
52 Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One
53 FDA Approves Atezolizumab for BRAF V600 Melanoma
54 Targeted Therapies Produce Durable Responses in BRAF V600E-Mutated Pediatric Low-Grade Gliomas
55 Study Moves the Needle for Melanoma Patients with Rare BRAF Mutations
56 Targetable BRAF and RAF1 alterations in advanced pediatric cancers.
57 European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC wi
58 Doublet for BRAF-Mutant Colon Cancer Heads to FDA
59 Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability
60 Trial of intermittent dabrafenib/trametinib dosing for BRAF-mutated melanoma fails
61 Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
62 BRAF Mutated Non-Small Cell Lung Cancer (NSCLC)
63 No-cost BRAF test aids therapeutic decision making
64 Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
65 QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer
66 Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC
67 Treatments Targeting Metastatic Colorectal Cancer with Mutated BRAF V600E Improve hrQoL
68 BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
69 BRAF V600E Mutation is Prognostic Indicator for Cutaneous Melanoma
70 Key Considerations for Detecting and Targeting BRAF Mutations
71 BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
72 Overcoming Resistance to Agents Treating BRAF Mutations in Colorectal Cancer
73 FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
74 Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer
75 Better Disease Biology Is Needed to Improve Melanoma Outcomes
76 Algazi Attests to Benefit of Continuous Dosing of BRAF/MEK Inhibitors in Melanoma
77 Prior ICI Associated With Longer PFS in BRAF V600E+ Melanoma Treated With Dabrafenib and Trametinib
78 Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
79 AACR Studies in BRAF-Mutated Melanoma Show Benefit of Combo Treatment, Continuous Dosing Strategies
80 Encorafenib + Cetuximab Approved for Treatment of mCRC with BRAF V600E mutation
81 A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Cancer
82 Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC
83 Dr. Kim on Treatment for BRAF-Mutant Colon Cancer
84 Dr. Pavlick on Sequencing Challenges in BRAF-Mutant Melanoma Treatment
85 V600E BRAF mutation strong prognostic indicator in colorectal liver cancer metastases
86 Encorafenib regimens confer quality-of-life, survival benefit in BRAF V600E-mutant metastatic colorectal cancer
87 BRAF/MEK inhibitor therapy induces response in metastatic melanoma with rare BRAF mutations
88 Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma
89 Expert Talks Progress, What's Next in Melanoma Treatment
90 First-Line Encorafenib Plus Binimetinib and Cetuximab Shows Promise in BRAF V600E+ mCRC
91 Treatment With Encorafenib/Binimetinib Leads to Improved, Longer Responses in Patients With BRAF Mutations
92 Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry
93 Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
94 Dabrafenib-trametinib combination confers durable survival benefit in BRAF -mutated metastatic melanoma
95 Dabrafenib, Trametinib Combination Shows Response and Duration in BRAF V600E Mutated Tumors
96 Novellus Raises $57M in Series C Funding
97 Updated BEACON: Doublet as Good as Triplet in Metastatic CRC
98 The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
99 Vemurafenib Active as Monotherapy in BRAF V600 NSCLC
100 Anti-EGFR therapy effective for certain patients with BRAF -mutant colorectal cancer